Primary |
Acute Lymphocytic Leukaemia |
25.0% |
B-cell Lymphoma |
25.0% |
Non-hodgkin's Lymphoma |
25.0% |
Leukaemia Plasmacytic |
18.8% |
T-cell Lymphoma |
6.3% |
|
Polyneuropathy |
25.0% |
Bacterial Sepsis |
12.5% |
Cellulitis |
12.5% |
Ileus Paralytic |
12.5% |
Renal Failure Acute |
12.5% |
Superinfection |
12.5% |
Wrong Drug Administered |
12.5% |
|
Secondary |
Non-hodgkin's Lymphoma |
11.6% |
B-cell Lymphoma |
10.7% |
Diffuse Large B-cell Lymphoma |
9.9% |
Acute Lymphocytic Leukaemia |
9.5% |
Hodgkin's Disease |
8.1% |
Adult T-cell Lymphoma/leukaemia |
6.9% |
Burkitt's Lymphoma |
6.6% |
Lymphoma |
6.5% |
Drug Use For Unknown Indication |
5.6% |
Product Used For Unknown Indication |
4.9% |
Prophylaxis |
4.7% |
Rhabdomyosarcoma |
2.5% |
Mantle Cell Lymphoma |
2.0% |
Multiple Myeloma |
1.9% |
Chronic Lymphocytic Leukaemia |
1.9% |
Hypertension |
1.6% |
Diffuse Large B-cell Lymphoma Stage Iv |
1.6% |
Chronic Myeloid Leukaemia |
1.5% |
Neoplasm Malignant |
1.0% |
Chemotherapy |
0.9% |
|
White Blood Cell Count Decreased |
15.3% |
Pulmonary Toxicity |
7.6% |
Interstitial Lung Disease |
6.5% |
Ejection Fraction Decreased |
5.4% |
Neutropenia |
5.4% |
Pneumonia |
5.2% |
Tremor |
5.2% |
Hepatitis B |
4.6% |
Polyneuropathy |
4.1% |
Septic Shock |
4.1% |
Thrombocytopenia |
4.1% |
Neuropathy Peripheral |
3.8% |
Progressive Multifocal Leukoencephalopathy |
3.8% |
Renal Impairment |
3.8% |
Sepsis |
3.8% |
Traumatic Lung Injury |
3.8% |
Multi-organ Failure |
3.5% |
Febrile Neutropenia |
3.3% |
Intracardiac Thrombus |
3.3% |
Lung Adenocarcinoma Stage I |
3.3% |
|
Concomitant |
Non-hodgkin's Lymphoma |
13.5% |
Neoplasm Malignant |
11.7% |
Lymphoma |
10.0% |
Drug Use For Unknown Indication |
8.7% |
Product Used For Unknown Indication |
8.4% |
Prophylaxis |
7.4% |
Acute Lymphocytic Leukaemia |
6.2% |
Burkitt's Lymphoma |
6.0% |
B-cell Lymphoma |
4.8% |
Diffuse Large B-cell Lymphoma |
4.4% |
Chemotherapy |
3.8% |
Stem Cell Transplant |
2.1% |
Adult T-cell Lymphoma/leukaemia |
1.9% |
T-cell Type Acute Leukaemia |
1.8% |
Hypertension |
1.8% |
Hodgkin's Disease |
1.7% |
Chronic Myeloid Leukaemia |
1.5% |
Multiple Myeloma |
1.5% |
Acute Biphenotypic Leukaemia |
1.4% |
Hiv Infection |
1.4% |
|
Vomiting |
19.3% |
White Blood Cell Count Decreased |
11.4% |
Pleural Effusion |
6.7% |
Somnolence |
6.3% |
Sepsis |
5.9% |
Renal Impairment |
5.1% |
Pneumocystis Jiroveci Pneumonia |
4.7% |
Thrombocytopenia |
3.9% |
Gastric Antral Vascular Ectasia |
3.5% |
Neutropenia |
3.5% |
Progressive Multifocal Leukoencephalopathy |
3.5% |
Death |
3.1% |
Drug Ineffective |
3.1% |
Malignant Neoplasm Progression |
3.1% |
Treatment Related Secondary Malignancy |
3.1% |
X-ray Abnormal |
3.1% |
Hepatitis Fulminant |
2.8% |
Interstitial Lung Disease |
2.8% |
Pancreatitis Acute |
2.4% |
Platelet Count Decreased |
2.4% |
|
Interacting |
Drug Use For Unknown Indication |
20.8% |
Acute Lymphocytic Leukaemia |
16.7% |
Prophylaxis |
15.7% |
Lymphoma |
15.5% |
B-cell Lymphoma |
5.4% |
Hypertension |
4.8% |
Product Used For Unknown Indication |
3.6% |
Haematopoietic Neoplasm |
3.2% |
Antibiotic Prophylaxis |
2.4% |
Infection |
2.4% |
Antifungal Treatment |
2.2% |
Diffuse Large B-cell Lymphoma |
1.8% |
Antifungal Prophylaxis |
1.6% |
Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
Constipation |
1.2% |
T-cell Type Acute Leukaemia |
0.8% |
Gastric Ulcer |
0.6% |
|
Ileus Paralytic |
32.1% |
Myalgia |
28.3% |
Drug Interaction |
13.2% |
Pyrexia |
9.4% |
Chest Discomfort |
3.8% |
Malaise |
3.8% |
Neuropathy Peripheral |
3.8% |
Hypokinesia |
1.9% |
Monoplegia |
1.9% |
Pain In Extremity |
1.9% |
|